Innovation and collaboration defined ESMO TAT Asia 2025. ESMO TAT’s first event in Asia attracted over 600 oncologists and healthcare professionals from 16 countries and territories.
🔬 Gene Solutions, in collaboration with the Medical Genetics Institute Vietnam, was proud to promote 11 innovative and promising studies at ESMO TAT Asia 2025 – selected from among 66 posters and 13 ePosters. Highlights of our research include:
❇️ AI-powered neoantigen & TCR selection for personalized cancer vaccines and TCR-T therapy;
❇️ ctDNA assays & multi-omics profiling for real-time monitoring and tailored treatment;
❇️ Novel immunotherapy targets – from KRASG12V bispecific engagers to NK ligand signatures;
❇️ Patient-derived organoid biobank for precision drug screening.
In addition, during the event, we had the opportunity to introduce two key innovations that are pushing the boundaries of precision oncology:
⭐ K-4CARE™ MAX: A comprehensive genomic and transcriptomic profiling solution for clinical research use only, featuring whole exome sequencing (DNA), 19,435 genes (RNA), and an ultra-sensitive ctDNA-MRD assay. It also includes exploratory biomarkers such as Tumor Neoantigen Burden and Tumor Microenvironment to support clinical trials in precision oncology.
⭐ DNASphere.AI Platform: A Unified AI Platform to improve Genetic Testing and Unlock Insights for the Rapid Identification and Validation of Novel Therapeutic Targets.
These efforts reflect our mission to transform cutting-edge science into accessible, region-specific cancer care—globally.
Thank you ESMOTAT ESMOTATAsia2025
